<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:xmi="http://www.omg.org/XMI" xmlns:pos="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmlns:cas="http:///uima/cas.ecore" xmlns:tweet="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos/tweet.ecore" xmlns:type8="http:///org/apache/uima/ruta/type.ecore" xmlns:morph="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/morph.ecore" xmlns:dependency="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/dependency.ecore" xmlns:type6="http:///de/tudarmstadt/ukp/dkpro/core/api/semantics/type.ecore" xmlns:type9="http:///org/apache/uima/trials/type.ecore" xmlns:noNamespace="http:///uima/noNamespace.ecore" xmlns:type="http:///de/tudarmstadt/ukp/dkpro/core/api/anomaly/type.ecore" xmlns:type7="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type.ecore" xmlns:type3="http:///de/tudarmstadt/ukp/dkpro/core/api/metadata/type.ecore" xmlns:type4="http:///de/tudarmstadt/ukp/dkpro/core/api/ner/type.ecore" xmlns:type5="http:///de/tudarmstadt/ukp/dkpro/core/api/segmentation/type.ecore" xmlns:type2="http:///de/tudarmstadt/ukp/dkpro/core/api/coref/type.ecore" xmlns:constituent="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/constituent.ecore" xmlns:chunk="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/chunk.ecore" xmi:version="2.0"><cas:NULL xmi:id="0"/><tcas:DocumentAnnotation xmi:id="2" sofa="1" begin="0" end="1649" language="x-unspecified"/><type9:OSMean xmi:id="3" sofa="1" begin="686" end="696"/><type9:OSMean xmi:id="4" sofa="1" begin="719" end="729"/><type9:PFSMean xmi:id="5" sofa="1" begin="785" end="795"/><type9:PFSMean xmi:id="9" sofa="1" begin="819" end="829"/><type9:ORR xmi:id="7" sofa="1" begin="1010" end="1014"/><type9:ORR xmi:id="8" sofa="1" begin="1028" end="1032"/><cas:Sofa xmi:id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: Prior to the 2008 advent of sorafenib, traditional cytotoxic agents&#13;&#10;were the therapeutic mainstay for patients with advanced hepatocellular carcinoma&#13;&#10;(HCC). We thus undertook a clinical study of sorafinib and conventional cytotoxic&#13;&#10;therapy for HCC, comparing efficacy and safety.&#13;&#10;METHODS: From January, 2002 to December, 2009, 173 patients with unresectable HCC&#13;&#10;were reviewed retrospectively. Among them, 44 (25.4%) had been treated with&#13;&#10;sorafenib, and the remainder had received cytotoxic therapy (CTX). We evaluated&#13;&#10;objective response rate (ORR), progression free survival (PFS), overall survival &#13;&#10;(OS), and toxicity profiles.&#13;&#10;RESULTS: Median OS of sorafinib was 23.0 weeks (95% CI, 8.1-37.9) vs 43.6 weeks&#13;&#10;(95% CI, 34.0-53.2) for CTX. Likewise, median PFS was 11.1 weeks (95% CI,&#13;&#10;6.5-15.8) vs 12.4 weeks (95% CI, 8.1-16.7) for sorafenib and CTX, respectively.&#13;&#10;Neither parameter differed significantly (OS, p?=?0.105; PFS, p?=?0.496). ORR and&#13;&#10;disease control rate for sorafenib were 2.3% and 52.3% vs 6.2% and 43.4% for CTX.&#13;&#10;CTX-treated patients experienced more Grade 3/4 neutropenia (19.7% vs 0% for&#13;&#10;sorafenib), while sorafenib therapy was more often linked to dermatologic&#13;&#10;toxicities (all grades), such as hand-foot skin reaction, rash, and pruritus.&#13;&#10;CONCLUSION: Although sorafenib has become the treatment of choice for advanced&#13;&#10;HCC, there are still unsettled issues regarding the optimal use of sorafenib. Our&#13;&#10;analysis indicates that conventional CTX can be another option of treatment for&#13;&#10;advanced HCC. To improve clinical outcomes, further prospective investigations&#13;&#10;which define the role of CTX are needed."/><cas:View sofa="1" members="2 3 4 5 9 7 8"/></xmi:XMI>